Member Info for flyingmachine

I thunk Punters is waiting for his £2 entry price before he jumps in....

sorry, couldn't resist. Of course, it is the number of Covid-19 cases still rising rapidly in many countries in the world, including closer to home, in Germany. It has also been going up in USA for the past 10 days, 32540 yesterday.

covid19 death rise (India up 15403 yesterday, South Africa up 4966 yesterday) so share will rise that is simple action , let see how much it will rise tomorrow may be 8 % when it close.

For the Covid-19 PCR test the next 10 days is the primary period when I hope to hear newsflow around FDA EUA, ICMR approval, new DIVOC distributor in India agreement and initial sales and contracts. WHO EUL approval should follow in early July. The focus of sales may initially be around India but I am expecting progress in other parts of the world to follow alongside or swiftly afterwards.

UserSteve, the copy of the slides used in the presentation are on the Genedrive website here.....

http://www.genedriveplc.com/company-reports/InvestorPresentationJune2020.pdf

The only difference in the pdf is that Genedrive have replaced the competitor names with generic 'Comp A', Comp B' etc.

jfellow, I assume you want to know about the Gov RTC ODX test (not Mologic tests) - it is an finger-prick antibody test LFD blood test used for a different purpose , to test if you have antibodies from a previous Covid-19 infection, as opposed to the planned Activa antigen POC LFT test which would be used to check if you have an active Covid-19 infection. The two tests are complimentary in the scheme of managing the spread of the virus, so not in direct competition.

If you want to see how the RTC ODX antibody LFT test would work, then watch the video below (sent out to members of the public taking part in Pillar 3 (REACT-2 antibody study), sub-study 3 (community ease of use testing). The REACT-2 programme is now in study 4 (Usability and validity of LFT self-testing in key workers). Study 4 is the final validation of performance of the antibody test and whether it can achieved the MHRA requirements for a POC antibody test in the hands of a consumer. I am expecting study 4 to complete by end of June. The MHRA requirements for antibody POC test performance are high - 98% sensitivity and specificity. I do not know the MHRA requirements for POC antigen test as these have not yet been published.

https://vimeo.com/415262977/04659145f9

I hope that helps.

Magsy, DYOR.

Magsy, I suggest you go and do the research over on the NCYT board and then report back for our information. We'll be all ears. Thanks.

Aprt from the Covid tests, we've already heard from DB about the potential annual market for the Genedrive AIHL test, £40m-£64m per year, with good profit margin and launching this autumn. But I thought it would be useful to look into the report from the Independent from earlier this year to really highlight the unique nature of this kind of test, run on the Genedrive POC instrument, which will also open the doors to further more tests of this kind being developed in the near future. Professor Bill Newman, whose University of Manchester team helped develop the test with Genedrive, is convinced that this kind of test....
"will open the door to early detection of more common conditions. His team is already working with genedrive plc on a similar rapid bedside test for stroke patients – to detect the one in 10 patients whose DNA makes them unable to metabolise clopidogrel, the common anti-platelet medication, and therefore have significantly worse outcomes. Models suggest similar tests could prevent several thousand of the 100,000 strokes suffered by people each year in the UK. It also opens up the possibility of using pharmacogenetics testing more widely by using biomarkers to target treatments more appropriately."

A very interesting read, this AIHL test is only the start.......
https://www.independent.co.uk/news/health/baby-deafness-gentamacin-test-genedrive-neonatal-care-nhs-a9294411.html

bapa, my suspicion is they need to drop to 3 to support their expected plan to reduce the social distancing from 2m to 1m (and allow them to further say they have 'successfully' managed the disease). They can't very well do that at level 4. It is so finely balanced as far as Covid spread is concerned in the UK, it could all tip in the wrong direction at any time.

I think there are many more new folk now that are finally putting put 2 and 2 together, using all the information this board has exposed over the past few weeks, the action of the recent bond conversion and its timing, the 'actors and stakeholders' involved, plus the recent Investor presentation last Friday. It paints a pretty picture, all based on facts and other related information.

So those standing on the sidelines better quickly read up on all the recent reserach and presentations because the train is leaving soon without you if you are not onboard!

GDR's last RNS, 2 days ago on the 16th June, stated that "genedrive expects to have gross cash balances of approximately £8.6 million" following the bond conversion. Add to that the near term cash flow from the "significant orders and commercial contracts" expected (DB's words from his presentation 6 days ago, not mine), then I do not see any further risk around 'cash in the bank'.

Agreed technick. DB is already on the case with the DHSC and it is moving through the milestones of the DHSC process. No doubt DB is expediting this through the GDR development team. It will be a 25-30 minute LAMP molecular assay run on the CE marked and military-approved desktop Genedrive PCR instrument......

https://testingmethods.crowdicity.com/post/3167180

Punter, final word. Not strange at all. Anyone who has done research will know the SP will be going up significantly from here. It is clear to me tuan does zero research. My opinion, full stop.

Punter, why are you agitated about this. Is he a pal of yours. I will not say any more on this matter.

Punter, look at his posts, and his flip-flopping, says it all, no credibility with me. He contributes nothing to this board except saying whatever suits his trading, up or down. I will stop there, I don't normally comment on other posters but he is particularly irritating to me.

tuan, you are such a micky taker, with zero credibility with me I'm afraid, your post from just 3 days ago, de-ramping (with absolutely not a shred of research done by you I expect)......

"tuan6 - 15 Jun 2020 20:16 - 75 coming
Nothing can changes it now . Until next 2 weeks time if they can't get the test out and don't have order this is going to 25" .

Jimmy, not disruptive at all for GDR PCR testing as I explained in a previous post........

RT-PCR molecular testing and POC testing are going to complement each other in the Covid testing landscape. RT-PCR will still be the clinical 'gold standard' test in the future where this is available in the professional clinical setting (hospitals, labs etc). There is certainly still a gap for POC testing yet to be filled. In that space there will be two variants - mobile PCR and antigen tests. Each will have there place according to the use case and accuracy required for the test and the clinical setting. The difference between POC antigen and mobile PCR testing are where they might be deployed (use cases) which will be dependent on the final accuracy that POC antigen testing can achieve. In professional environment use cases (football or other professional sporting clubs, clinics, large companies etc) I expect mobile PCR testing to hold its own due to superior accuracy and importance of this higher accuracy and reliability in these environments. POC antigen testing will find its place in mass screening but to what extent will all come down to the final antigen testing accuracy, they are not as accurate as PCR molecular tests by their very nature. MHRA has not yet published the TPPs for POC antigen tests.

In fact, there was a Cytiva webinar this evening that talked about the challenges of achieving 'clinically relevant' sensitivity and specificity in a POC antigen test, not impossible, but difficult. The Aptimer based POC antigen test that is shown in the link is old news really but it is more a competitor for AVCT POC and Sona Nanotech POC antigen tests, not Genedrive.

FatherTed, a pretty good synopsis.

I would add that they all agreed that it was important to achieve the level of performance to make the LFT test 'clinically relevant' - although they are expediting as much as possible this will take time to develop and test through proper clinical validation. They also are working with authorities to align with the required target product profile for these kind of tests.

So it seemed clear they are still working through the performance issues but all expressed confidence at the end that it was doable and that they would eventually achieve it.

There were a couple of contradictory comments but that's understandable due to the mix of scientific and commercial roles on the panel.

They realised after the event that perhaps it's not good etiquette to name names on the comparison slide but it is not as though the information is not public knowledge, they just put it all on one slide. All the information is still in the video though, so just shows how well GDR have done in creating their new top tier Covid19 test.